Copyright
©The Author(s) 2023.
World J Clin Cases. Apr 26, 2023; 11(12): 2621-2630
Published online Apr 26, 2023. doi: 10.12998/wjcc.v11.i12.2621
Published online Apr 26, 2023. doi: 10.12998/wjcc.v11.i12.2621
Table 1 Summary of trials, case reports and retrospective studies on dual biological therapy for inflammatory bowel disease
| Ref. | Study type | No. of patients | Disease | Treatment used |
| Sands et al[14], 2007 | RCT | 79 | CD | IFX + natalizumab |
| Anita and Michael[16], 2016 | CR | 1 | CD | VDZ + ADA |
| Bethge et al[17], 2017 | CR | 1 | UC | VDZ + ETN |
| Liu and Loomes[9], 2017 | CR | 1 | CD | UST + VDZ |
| Huff-Hardy et al[10], 2017 | CR | 1 | CD | UST + VDZ |
| Roblin et al[19], 2018 | CR | 1 | UC | GOL + VDZ |
| Buer et al[20], 2018 | CS | 10 | 4 × CD, 6 × UC | Anti-TNF + VDZ |
| Mao et al[21], 2018 | CS | 4 | CD | VDZ + UST/GOL |
| Olbjørn et al[11], 2020 | CS | 13 | 9 × CD, 4 × UC | IFX + UST/VDZ |
| Glassner et al[22], 2020 | Retrospective | 50 | CD + UC | UST + ANTI-TNF/VDZ, tofacitinib + VDZ/UST/anti-TNF, Cyclosporin, rituximab, SEC, leflunomide, tacrolimus |
| Yang et al[23], 2020 | Retrospective | 22 | CD | VDZ + UST/anti-TNF, UST + anti-TNF |
| Privitera et al[24], 2020 | Retrospective | 16 | 11 × CD, 5 × UC | UST + CZP/IFX/ADA/VDZ, VDZ + ADA/SEC/IFX/CZP/aprelimast |
| Kwapisz et al[26], 2021 | Retrospective | 15 | 14 × CD, 1 × UC | VDZ + anti-TNF/UST, UST + anti-TNF/VDZ |
| Goessens et al[27], 2021 | Retrospective | 98 | 58 × CD, 40 × UC | ADA + VDZ/UST, VDZ + INF + azathioprine, VDZ + UST + azathioprine, UST + ETN, IFX + VDZ + methotrexate, CZP + VDZ + methotrexate |
| No author listed[15], 2022 | RCT | 214 | UC | GOL + guselkumab |
Table 2 Summary of infections reported in randomised controlled trial and case studies of patients on dual biologic therapy for inflammatory bowel disease
| Ref. | Infections documented |
| Sands et al[14], 2007 | Nasopharyngitis |
| Buer et al[20], 2018 | Tonsillitis × 2 |
| Sinusitis × 1 | |
| Olbjørn et al[11], 2020 | Skin infection |
| Mao et al[21], 2018 | Clostridium difficile × 2 |
| Hand, foot and mouth disease | |
| Influenza | |
| Yang et al[23], 2020 | Pneumonia |
| Clostridium difficile | |
| Actinetobacter bacteraemia | |
| Privitera et al[24], 2020 | Perianal abscess |
| Kwapisz et al[26], 2021 | Salmonella |
| Clostridium difficile | |
| 4 × patients needing antibiotics | |
| Goessens et al[27], 2021 | Osteomyelitis |
| Enterocutaneous fistula infection | |
| Perianal abscess | |
| Viral URTI | |
| Campylobacter | |
| Pneumonia | |
| Herpetic meningoencephalitis | |
| Oesophageal candidiasis | |
| Influenza |
- Citation: McCormack MD, Wahedna NA, Aldulaimi D, Hawker P. Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease. World J Clin Cases 2023; 11(12): 2621-2630
- URL: https://www.wjgnet.com/2307-8960/full/v11/i12/2621.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i12.2621
